ImageneBio, Inc. Contract Liability (Deferred Revenue)
ImageneBio, Inc. (IMA) had Contract Liability (Deferred Revenue) of $659.00 thousand as of 2023-09-30, per its 10-Q filed 2023-11-09.
Discontinued › Balance Sheet › Liabilities
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2024-03-12
- 2023-09-30: Contract with Customer, Liability, Current $659.00K.
- 2023-06-30: Contract with Customer, Liability, Current $1.84M.
- 2023-03-31: Contract with Customer, Liability, Current $3.85M.
- 2022-12-31: Contract with Customer, Liability, Current $9.16M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2023-09-30 | $659.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | $1.84M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $3.85M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $9.16M 10-K · filed 2024-03-12 |
| 2022-09-30 | $12.11M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $17.19M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $16.75M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $17.10M 10-K · filed 2023-03-14 |
| 2021-09-30 | $22.57M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $22.47M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $22.34M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $20.62M 10-K · filed 2022-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |